The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. / Jürgens, Mikkel; Schou, Morten; Hasbak, Philip; Kjær, Andreas; Wolsk, Emil; Zerahn, Bo; Brandt-Jacobsen, Niels H.; Gæde, Peter; Rossing, Peter; Faber, Jens; Inzucchi, Silvio E.; Gustafsson, Finn; Kistorp, Caroline.

In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 2023, p. 2888-2896.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jürgens, M, Schou, M, Hasbak, P, Kjær, A, Wolsk, E, Zerahn, B, Brandt-Jacobsen, NH, Gæde, P, Rossing, P, Faber, J, Inzucchi, SE, Gustafsson, F & Kistorp, C 2023, 'The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 2888-2896. https://doi.org/10.1111/dom.15183

APA

Jürgens, M., Schou, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Brandt-Jacobsen, N. H., Gæde, P., Rossing, P., Faber, J., Inzucchi, S. E., Gustafsson, F., & Kistorp, C. (2023). The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 25(10), 2888-2896. https://doi.org/10.1111/dom.15183

Vancouver

Jürgens M, Schou M, Hasbak P, Kjær A, Wolsk E, Zerahn B et al. The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023;25(10):2888-2896. https://doi.org/10.1111/dom.15183

Author

Jürgens, Mikkel ; Schou, Morten ; Hasbak, Philip ; Kjær, Andreas ; Wolsk, Emil ; Zerahn, Bo ; Brandt-Jacobsen, Niels H. ; Gæde, Peter ; Rossing, Peter ; Faber, Jens ; Inzucchi, Silvio E. ; Gustafsson, Finn ; Kistorp, Caroline. / The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. In: Diabetes, Obesity and Metabolism. 2023 ; Vol. 25, No. 10. pp. 2888-2896.

Bibtex

@article{11ab0cc2aa8840b4a4e03d7e578448cf,

title = "The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes",

abstract = "Aims: To investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events. Materials and Methods: In this prespecified substudy of the randomized, placebo-controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between-group change in mGFR, measured by the 51Cr-EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included. Results: From April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention-to-treat analysis. Treatment with empagliflozin reduced mGFR by −7.9 mL/min (95% confidence interval [CI] −11.1 to −4.7; P < 0.001), estimated ECV by −192.5 mL (95% CI −318.0 to −66.9; P = 0.003) and estimated PV by −128.9 mL (95% CI −218.0 to 39.8; P = 0.005) at Week 13. Conclusions: Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.",

keywords = "extracellular volume, GFR, heart failure, plasma volume, SGLT2 inhibitor, type 2 diabetes",

author = "Mikkel J{\"u}rgens and Morten Schou and Philip Hasbak and Andreas Kj{\ae}r and Emil Wolsk and Bo Zerahn and Brandt-Jacobsen, {Niels H.} and Peter G{\ae}de and Peter Rossing and Jens Faber and Inzucchi, {Silvio E.} and Finn Gustafsson and Caroline Kistorp",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",

year = "2023",

doi = "10.1111/dom.15183",

language = "English",

volume = "25",

pages = "2888--2896",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "10",

}

RIS

TY - JOUR

T1 - The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes

AU - Jürgens, Mikkel

AU - Schou, Morten

AU - Hasbak, Philip

AU - Kjær, Andreas

AU - Wolsk, Emil

AU - Zerahn, Bo

AU - Brandt-Jacobsen, Niels H.

AU - Gæde, Peter

AU - Rossing, Peter

AU - Faber, Jens

AU - Inzucchi, Silvio E.

AU - Gustafsson, Finn

AU - Kistorp, Caroline

PY - 2023

Y1 - 2023

N2 - Aims: To investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events. Materials and Methods: In this prespecified substudy of the randomized, placebo-controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between-group change in mGFR, measured by the 51Cr-EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included. Results: From April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention-to-treat analysis. Treatment with empagliflozin reduced mGFR by −7.9 mL/min (95% confidence interval [CI] −11.1 to −4.7; P < 0.001), estimated ECV by −192.5 mL (95% CI −318.0 to −66.9; P = 0.003) and estimated PV by −128.9 mL (95% CI −218.0 to 39.8; P = 0.005) at Week 13. Conclusions: Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.

AB - Aims: To investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events. Materials and Methods: In this prespecified substudy of the randomized, placebo-controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between-group change in mGFR, measured by the 51Cr-EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included. Results: From April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention-to-treat analysis. Treatment with empagliflozin reduced mGFR by −7.9 mL/min (95% confidence interval [CI] −11.1 to −4.7; P < 0.001), estimated ECV by −192.5 mL (95% CI −318.0 to −66.9; P = 0.003) and estimated PV by −128.9 mL (95% CI −218.0 to 39.8; P = 0.005) at Week 13. Conclusions: Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.

KW - extracellular volume

KW - GFR

KW - heart failure

KW - plasma volume

KW - SGLT2 inhibitor

KW - type 2 diabetes

U2 - 10.1111/dom.15183

DO - 10.1111/dom.15183

M3 - Journal article

C2 - 37395341

AN - SCOPUS:85164205091

VL - 25

SP - 2888

EP - 2896

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 10

ER -

ID: 365745925

Department of Biomedical Sciences